We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Statins May Protect Against Dementia

By Biotechdaily staff writers
Posted on 30 Jul 2007
Statins are not all the same when it comes to their potential to guard against dementia, according to a recent study. More...
New findings suggest that simvastatin is linked with a lower incidence of dementia and Parkinson's disease. Disagreement over whether statins could protect against these disorders has meant the benefits to dementia sufferers to date have been unclear.

Statins are cholesterol-lowering drugs used by those individuals with heart disease. An international team led by Benjamin Wolozin, M.D., from the Boston University School of Medicine (Boston, MA, USA) used data from the US Veterans Affairs Database, which contains diagnostic, medication, and demographic information on 4.5 million subjects. The researchers utilized statistical models to compare different statins, evaluating data on over 700,000 simvastatin users and more than 50,000 atorvastatin users. The investigators targeted those aged 65 or over with no prior diagnosis of Alzheimer's disease, who had been taking statins for at least seven months.

The researchers discovered that for individuals aged 65 and over, simvastatin was associated with a considerably decreased number of cases of dementia and Parkinson's disease. The researchers also made the unexpected finding that not all statins are equal when it comes to dementia or Parkinson's disease. A small decrease in dementia cases was seen among those who regularly take atorvastatin, which did not reach a level of statistical significance. Lovastatin was not found to have any significant effect on dementia, and neither atorvastatin nor lovastatin were linked with a decrease in the number of cases of Parkinson's disease.

"The strength of reduction of incidence of dementia observed with simvastatin is striking,” the investigators wrote in their article. Additional research should confirm that it is simvastatin's biologic mode of action instead of a statistical bias at work. Earlier research has studied whether statin treatment is helpful for dementia sufferers or those at risk of dementia, but such studies have lead to some conflicting results. The current study gives more accurate results as it has significant statistical strength, according to the researchers, and incorporates existing data to investigate dementia and Parkinson's disease comprehensively.

The study was published in the online open access journal BMC Medicine July 19, 2007.


Related Links:
Boston University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.